Breakthrough: Clinical Trials Of Umifenovir Prove Successful In Treating Covid, Says CDRI

Breakthrough: Clinical Trials Of  Umifenovir Prove Successful In Treating Covid, Says CDRIIndia kick starts the world’s largest Covid-19 vaccination drive (Representative Image)

In a major achievement in the fight against the coronavirus pandemic, the Central Drug Research Institute (CDRI) has said that clinical trials of antiviral drug, Umifenovir, in treatment of Covid-19, have been a successful exercise.

The trial of Umifenovir on 132 Covid patients showed that, if proper dose is given twice daily for five days, the drug can effectively reduce viral load to zero in mild or moderate symptomatic and asymptomatic patients by checking multiplication of the virus.

The trials were done at KGMU, Ram Manohar Lohia Institute of Medical Sciences (RMLIMS) and Era's Lucknow Medical College and Hospital (ELMCH).

"Since Umifenovir is a broad-spectrum antiviral and is being used as a safe over-the-counter drug for influenza and pneumonia for over 20 years in Russia, China and other countries. The first two trials were not mandatory."

The CDRI, therefore, directly went for phase-III trial, conducted on 132 patients either admitted in hospital or in home quarantine under the supervision of these hospitals," CDRI director Prof Tapas Kundu said.

"In a study, double-blind mode improves the reliability of results by preventing bias when doctors evaluate patient outcomes. The results showed that viral load in mild, moderate or asymptomatic patients after being given two doses of Umifenovir (800mg), twice a day, became zero in an average of five days. Patients did not experience any side-effects and their symptoms also did not turn severe," he said.

Studies by CDRI in collaboration with CSIR-IMT, Chandigarh, also showed that Umifenovir exhibits good cell culture inhibition of SARSCov2, which suggests that the drug inhibits the entry of SARS-Cov2 virus into human cells.

Kundu said the institute was getting the dosage plan patented as it had not been used earlier for Covid-19.

"The Drug Controller General of India (DCGI) has evaluated the clinical trials report and in view of the highly encouraging results and he has asked the team to continue the studies on more mild, asymptomatic patients for grant of emergency approval of the drug," he added.

It shoud be noted that earlier in May 2021, the DCGI had approved anti-COVID drug developed by DRDO for emergency use.

CDRI chief scientist Prof R Ravishankar said, "Umifenovir will be economical for treating Covid-19 patients as it is around 54 per cent cheaper compared to current medication. The drug is safe for pregnant women and children. We are also looking into the possibility of Umifenovir syrup for children and also in powder form for puff inhalers."

With IANS Inputs